Skip to content

Effect of a millet enriched liquid nutrition on muscle strength and recovery in critically ill patients

Effect of Millet Enriched Enteral Nutrition on Muscle Wasting, Functional Recovery and Clinical Outcomes in Critically Ill Patients: A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/114191
Enrollment
430
Registered
2026-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: -

Interventions

Intervention1: Millet Enriched Enteral Nutrition: Intervention group will receive a millet-enriched enteral nutrition formula containing foxtail millet and finger millet as the primary cereal compone

Sponsors

All India Institute of Medical Sciences, Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older. 2. Expected ICU stay 72 hours or longer. 3. Hemodynamically stable. 4. Clinical decision to start enteral nutrition within 24 to 48 hours of ICU admission. 5. Able to receive gastric or post pyloric tube feeding. 6. Patients admitted to the ICU for any acute medical, surgical, or neurological illness.

Exclusion criteria

Exclusion criteria: 1. Conditions where enteral feeding is contraindicated, including bowel obstruction, bowel ischemia, active gastrointestinal bleeding, recent major gastrointestinal surgery, severe ileus, abdominal compartment syndrome, or high output proximal gastrointestinal fistula. 2. Known neuromuscular disorders e.g., myasthenia gravis, muscular dystrophy, motor neuron disease, Guillain Barre syndrome. 3. Pre existing muscle wasting or sarcopenia prior to ICU admission. 4. Known allergy or intolerance to millet or millet based products. 5. Body Mass Index less than 18.5 kilograms per square metre.

Design outcomes

Primary

MeasureTime frame
Muscle wasting assessed by change in quadriceps muscle thickness measured using ultrasonography.Timepoint: Baseline Day 1, Day 7, and Day 14 or ICU discharge, whichever occurs earlier.

Secondary

MeasureTime frame
Functional recovery assessed using the ICU Mobility Scale.Timepoint: Baseline Day 1, Day 7 and Day 14 or until ICU discharge, whichever occurs earlier.;Handgrip strength measured using a hydraulic hand dynamometer.Timepoint: Baseline Day 1, Day 7, and Day 14 or ICU discharge, whichever occurs earlier.;Gastrointestinal intolerance to enteral nutrition.Timepoint: Assessed daily during ICU stay until Day 14 or ICU discharge, whichever occurs earlier.;Duration of invasive mechanical ventilation.Timepoint: Up to ICU discharge or Day 28, whichever occurs earlier.;ICU length of stay.Timepoint: Up to ICU discharge or Day 28, whichever occurs earlier.;ICU mortality.Timepoint: Up to ICU discharge or Day 28, whichever occurs earlier.

Countries

India

Contacts

Public ContactPriya Sharma

AIIMS Jodhpur Rajasthan

sk.aiims17@gmail.com8475000293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026